CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02306161
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-04T12:58:48.694924+00:00
Published At: 2022-07-01T00:00:00+00:00
Record Updated At: 2026-06-03
Results Posted At: 2022-07-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Ewing Sarcoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Bone Marrow", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone", "Peripheral Primitive Neuroectodermal Tumor of Soft Tissues"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-03"
protocolSection.identificationModule.nctId: "NCT02306161"
protocolSection.identificationModule.officialTitle: "Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-07-01"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.